Indeed, our HSC4 results demonstrated that nivolumab decreased human T cells in NOG mice, especially at tumor sites, whereas the increase of T cells was oppositely induced in NOG-FcγR−/− mice, which would support this possibility. This evidence concerns the gene FCGR2A and neoplasm.